Advance Dx, Inc. Announced They Have Been Issued a Patent From the US Patent Office for a Serum Separator Blood Collection Card

Share Article

Advance Dx, Inc. newly patented serum separating blood collection card to enhance efforts to screen all Americans for early disease detection.

Advance Dx, Inc. announced the issuance of US Patent No. 8,062,608 from the US Patent office, which relates to the ADx 100 serum separating blood collection card for use by the clinical laboratory industry. This marks the first time such a patented collection device has been made available for all laboratories.

“Under the Affordable Health Care Act, routine blood screening will become an important part of the American health care system, helping to fight disease at its earliest stage. The newly patented card will help screeners and laboratories to perform this important task in an efficacious manner,” said Ned Bedrio, president of Advance Dx.

Ned Bedrio, President of Advance Dx, Inc. noted, “To date, dry blood collection has been performed using whole blood. The Advance Dx 100 card is an alternative collection method similar to an SST tube, where red cells are separated from the serum without the need of a centrifuge. This enables the laboratory to perform serum based tests without red cell contamination using a dry blood collection format. The processing of the dried blood is also made easier than conventional dried blood. No specific or specialized analyzers are required, other than the in-house analyzers most laboratories presently have.

The ADx100 blood collection card allows micro sample acquisition for laboratories interested in pursuing the two billion dollars and still growing screening business in both corporate health and wellness markets, as well as disease management programs. A full array of diagnostic testing including Lipid Panel (Cholesterol, Triglyceride, LDL and HDL) with a fasting Glucose, Direct LDL, Vitamin D, Testosterone, Prostate Specific Antigen (PSA), Thyroid Stimulating Hormone (TSH), Hemoglobin A1c (HbA1c), High Sensitivity C Reactive Protein (hsCRP) and Cotinine are currently being performed on the ADx 100 card. Since its inception in 2008, Advance Dx, Inc. has offered simplicity to the patient and screener during collection while being balanced by simplicity in the laboratory by having a one step process in rehydration of the serum sample. Such simplicity in design has paid off in that most serum based tests can be performed using one unique patented design. Depending on sample size requirements of the analyzer most serum based tests can be performed by utilizing the ADx 100 card.

The ADx 100 serum separating blood collection card is presently being utilized by two national and many local laboratories. This alternative way to collect blood samples is the latest in advances from Advance Dx in its ongoing quest to provide alternative easier collection devices for clinical blood testing as well as allowing laboratories or pharmaceutical companies to develop additional revenues.

For additional information about the blood collection card or about Advance Dx, Inc., contact Ned Bedrio direct at 877.239.1001, ext. 701 or email nbedrio(at)ADx100(dot)com.
Or visit us on the web at http://www.ADx100.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ned Bedrio
Visit website